Modulation of angiogenesis by thyroid hormone and hormone analogues: Implications for cancer management

Shaker A. Mousa, Hung Yun Lin, Heng Yuan Tang, Aleck Hercbergs, Mary K. Luidens, Paul J. Davis

研究成果: 雜誌貢獻文章同行評審

59 引文 斯高帕斯(Scopus)

摘要

Acting via a cell surface receptor on integrin αvβ3, thyroid hormone is pro-angiogenic. Nongenomic mechanisms of actions of the hormone and hormone analogues at αvβ3 include modulation of activities of multiple vascular growth factor receptors and their ligands (vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor, epidermal growth factor), as well as of angiogenic chemokines (CX3 family). Thyroid hormone also may increase activity of small molecules that support neovascularization (bradykinin, angiotensin II) and stimulate endothelial cell motility. Therapeutic angio-inhibition in the setting of cancer may be opposed by endogenous thyroid hormone, particularly when a single vascular growth factor is the treatment target. This may be a particular issue in management of aggressive or recurrent tumors. It is desirable to have access to chemotherapies that affect multiple steps in angiogenesis and to examine as alternatives in aggressive cancers the induction of subclinical hypothyroidism or use of antagonists of the αvβ3 thyroid hormone receptor that are under development.
原文英語
頁(從 - 到)463-469
頁數7
期刊Angiogenesis
17
發行號3
DOIs
出版狀態已發佈 - 2014

ASJC Scopus subject areas

  • 癌症研究
  • 生理學
  • 臨床生物化學
  • 醫藥 (全部)

指紋

深入研究「Modulation of angiogenesis by thyroid hormone and hormone analogues: Implications for cancer management」主題。共同形成了獨特的指紋。

引用此